Synovitis: Clinical Trials

3 trials for Synovitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Phase 21Completed 1

Follow Synovitis: new trials by email Literature Review of Synovitis trials Research Report on Synovitis

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Tolbutamide, Midazolam, Pexidartinib - Drug Interaction Potential
Phase 1CompletedDaiichi Sankyo322018-02-262021-05-14
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
FPA008 - Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
Phase 1 / Phase 2CompletedFive Prime Therapeutics, Inc.662015-06-012021-08-31
Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients
15-O labeled water - Rheumatoid Arthritis
Phase 1CompletedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)102001-04-012008-03-04

Narrower conditions

Synovitis, Pigmented Villonodular (2)  ·  Arthritis (1)  ·  Arthritis, Rheumatoid (1)  ·  Giant Cell Tumor of Tendon Sheath (1)

Broader conditions

Joint Diseases (3)  ·  Musculoskeletal Diseases (3)  ·  Giant Cell Tumors (2)  ·  Muscular Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Connective Tissue (2)  ·  Neoplasms, Connective and Soft Tissue (2)  ·  Tendinopathy (2)  ·  Autoimmune Diseases (1)  ·  Connective Tissue Diseases (1)  ·  Giant Cell Tumor of Tendon Sheath (1)  ·  Immune System Diseases (1)  ·  Rheumatic Diseases (1)

Interventions

Bro protein, Drosophila (1)  ·  Midazolam (1)  ·  Tolbutamide (1)  ·  cabiralizumab (1)  ·  pexidartinib (1)

Sponsors

Daiichi Sankyo (1)  ·  Five Prime Therapeutics, Inc. (1)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)

Countries

United States (3)  ·  Netherlands (2)  ·  France (1)  ·  New Zealand (1)  ·  Poland (1)  ·  South Korea (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Results publications

PMID 33289960